Table 4.

Multivariable Analysis For The Association Between Structural Glaucoma Severity And PIPR Parameters

	Adjusted Model
	Blue 6-Second PIPR Amplitude, %			Red 6-Second PIPR Amplitude, %			Net PIPR Change, %			Net PIPR, mm
Variables	Regression Coefficient	95% CI	P Value	Regression Coefficient	95% CI	P Value	Regression Coefficient	95% CI	P Value	Regression Coefficient	95% CI	P Value
RNFL thickness (per 10-µm thinning)	1.29	0.72, 1.87	<0.001	0.01	−0.51, 0.52	0.98	−0.70	−1.26, −0.14	0.015	−0.03	−0.05, −0.001	0.044
Age (per year)	−0.01	−0.11, 0.09	0.80	−0.07	−0.16, 0.01	0.10	−0.03	−0.13, 0.07	0.57	−0.003	−0.01, 0.002	0.26
Sex (male vs female)	−1.84	−3.90, 0.23	0.08	−1.47	−3.32, 0.37	0.12	0.88	−1.15, 2.92	0.39	0.04	−0.05, 0.14	0.37
Body mass index (per BMI)	−0.07	−0.38, 0.24	0.65	0.06	−0.22, 0.35	0.67	0.12	−0.20, 0.44	0.45	0.004	−0.01, 0.02	0.64
Hypertension (yes vs no)	0.94	−1.15, 3.04	0.38	−0.36	−2.19, 1.47	0.70	1.17	−0.90, 3.24	0.27	0.05	−0.05, 0.15	0.30
Diabetes (yes vs no)	−0.64	−3.18, 1.91	0.62	0.98	−1.25, 3.21	0.39	0.81	−1.68, 3.30	0.52	0.05	−0.06, 0.17	0.38
Oral medication (antihistamine and dopaminergic) use (yes vs. no)	−1.75	−5.18, 1.68	0.31	−2.88	−5.73, −0.03	0.047	0.47	−2.75, 3.69	0.77	0.06	−0.09, 0.20	0.46
Cataract surgery (yes vs. no)	1.97	−0.23, 4.18	0.08	1.02	−0.91, 2.95	0.30	−0.68	−2.85, 1.49	0.54	−0.02	−0.12, 0.08	0.69
Axial length (per mm)	−0.87	−1.53, −0.21	0.01	−0.41	−0.99, 0.17	0.16	0.37	−0.29, 1.02	0.27	0.01	−0.02, 0.04	0.40
Topical alpha2-adrenergic receptor agonist use (yes vs no)	4.43	1.15, 7.70	0.008	2.35	−0.35, 5.06	0.09	−2.26	−5.46, 0.95	0.17	−0.10	−0.25, 0.05	0.18

BMI, body mass index.

Adjusted for the potential confounders in Table 1 (age, sex, body mass index, hypertension, diabetes, oral medication [antihistamine and dopaminergic] use, cataract surgery, axial length, and topical alpha₂-adrenergic receptor agonist use).